Nebenwirkungen · Edarbi
Edarbi 20 mg tablets Edarbi 40 mg tablets Edarbi 80 mg tablets · Abschnitt 4.8 · PDF-Seite 7
HOS-125067 · Präparat HOS-095985
Summary of the safety profile Edarbi at doses of 20, 40 or 80 mg has been evaluated for safety in clinical studies in adult patients treated for up to 56 weeks. In these clinical studies, adverse reactions associated with treatment with Edarbi were mostly mild or moderate, with an overall incidence similar to placebo. The most common adverse reaction was dizziness. The incidence of adverse reactions with this treatment was not affected by gender, age, or race. Adverse reactions were reported at a similar frequency for the Edarbi 20 mg dose as with the 40 and 80 mg doses in one placebo controlled study.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-29T02:00:00Z · SHA-256 8230af08fa75f2b692602f2410b0b929dc05d56ba2a9d3e11787a1a2657b52b8 · Passage 8d7fe0e9065ddb504ad598f0f7a88204c7e0b458b351707b7421c84275e239d8 · Zeichen 0–609 im Abschnitt